They may be useful in some patients with severe hypertri- glyceridemia, but in the present document they are not listed as LDL-lowering drugs. See Table S4 in the Web Supplement. 3.2.3. Nonstatin Add-on Drugs to Statin Therapy Under certain circumstances, nonstatin medications (ezetimibe, bile acid sequestrants, and PCSK9 inhibi- tors) may be useful in combination with statin therapy. The addition of a bile acid sequestrant or ezetimibe to a statin regimen increases the magnitude of LDL-C lower- ing by approximately 15% to 30% and 13% to 20%, The addition of a PCSK9 inhibi- tor to a statin regimen has been shown to further re- duce LDL-C levels by 43% to 64%.S3.2.3-3,S3.2.3-4 See Table S5 in the Web Supplement. 4. PATIENT MANAGEMENT GROUPS 4.1. Secondary ASCVD Prevention Recommendations for Statin Therapy Use in Patients With ASCVD Referenced studies that support recommendations are summarized in Online Data Supplements 6 to 8 and in the Systematic Review Report. 